NASDAQ$CCRN

Cross Country Healthcare Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Cross Country Healthcare's third quarter performance exceeded expectations, driven by advanced technology and strong execution amidst normalizing market conditions.

Cross Country Healthcare reported strong Q3 2022 results, exceeding updated guidance ranges for revenue, Adjusted EBITDA, and Adjusted EPS. The company saw double-digit year-over-year revenue growth across both segments and repurchased 1 million shares of common stock. Consolidated revenue was $636.1 million, a 70% increase year-over-year, and net income attributable to common stockholders was $34.8 million.

  • Revenue, Adjusted EBITDA, and Adjusted EPS exceeded previously updated guidance ranges.
  • Double-digit year-over-year revenue growth was achieved across both segments.
  • Adjusted EBITDA margin was 10.0%.
  • 1 million shares of common stock were repurchased for $24.3 million.

Headline financials

Total Revenue

$636M

Previous: $375M+69.7%
EPS (adj)

$1.07

Previous: $0.61+75.4%
Capital Expenditures

-$6.76M

Previous: -$4.89M-38.3%
Free Cash Flow

$28M

Previous: $18.5M+51.2%
Net Income

$34.8M

Previous: $23.4M+48.5%
Operating Income

$52.2M

Previous: $26.4M+97.3%
Gross Profit

-$493M

Previous: -$291M-69.2%
Cash & Equivalents

$30.3M

Previous: $842K+3501.0%
Total Assets

$883M

Previous: $520M+69.6%
Stock-Based Comp

$1.49M

Previous: $1.77M-15.8%

Revenue & EPS history

Cross Country Healthcare · Revenue · Quarterly

$636M

Q3 2022+69.7%vs Q3 2021
Beat estimate in 11 of 15 quarters(73%)
ActualEstimate

Revenue by segment

Cross Country Healthcare · $636M total across 2 segments · Q3 2022

  • Nurse and Allied Staffing
    $612M+71.9%
  • Physician Staffing
    $23.8M+27.0%

Forward guidance

The company provided guidance for Q4 2022, expecting revenue between $590 million and $600 million, a gross profit margin between 22.3% and 22.8%, Adjusted EBITDA between $52.0 million and $57.0 million, and Adjusted EPS between $0.85 and $0.95.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

-2.7%

Avg return

Earnings day

-1.5%

Avg return

5 days after

+0.5%

Avg return

30 days after

44%

28 / 64 earnings

Positive

+24.6%

Q3 2021

Best reaction

-33.6%

Q2 2010

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+0.8%+0.4%+0.8%
Q4 2025+8.2%+7.9%+0.5%
Q3 2025-14.1%-7.2%-32.9%
Q1 2025+0.4%+0.8%-6.7%
Q4 2024+0.3%-6.0%-13.9%
Q3 2024+7.2%-6.1%+57.9%
Q2 2024-2.7%-8.2%-17.3%
Q1 2024-4.9%-9.0%-14.1%
Q4 2023-2.7%-0.3%+5.7%
Q3 2023-14.0%-19.0%-10.7%
Q2 2023-14.7%-14.0%-3.8%
Q1 2023+5.1%+9.9%+26.1%
Q4 2022-5.6%+3.2%-13.2%
Q3 2022-2.5%-11.3%-2.8%
Q2 2022-13.7%-14.1%-7.6%
Q1 2022-2.6%-7.1%+0.9%
Q4 2021-1.5%+6.6%+2.4%
Q3 2021+24.6%+18.0%+21.1%
Q2 2021+23.0%+14.6%+29.7%
Q1 2021+16.5%+24.0%+17.4%
Q4 2020+18.9%+24.6%+33.8%
Q3 2020-5.0%-3.0%+9.3%
Q2 2020+9.6%+4.7%+1.6%
Q1 2020-4.8%-2.0%+7.6%
Q4 2019+0.4%-12.2%-27.7%
Q3 2019+14.2%+16.9%+10.9%
Q2 2019-0.8%-5.5%+5.6%
Q1 2019+4.7%+18.7%+0.9%
Q4 2018-3.6%-11.6%-22.5%
Q3 2018+7.8%+3.4%+2.7%
Q2 2018-30.9%-26.0%-14.7%
Q1 2018-16.7%-11.0%-4.3%
Q4 2017-18.8%-13.6%-15.8%
Q3 2017-9.6%-13.8%-2.6%
Q2 2017+3.1%+1.2%+2.5%
Q1 2017-13.0%-15.1%-16.7%
Q4 2016+3.4%-5.3%-7.2%
Q3 2016+22.9%+24.3%+31.7%
Q2 2016-11.5%-17.0%-14.2%
Q1 2016+10.0%
Q4 2015-21.9%
Q3 2015+9.5%
Q2 2015+10.1%
Q1 2015-4.6%
Q4 2014-9.6%
Q3 2014-0.5%
Q2 2014+1.8%
Q1 2014-14.3%
Q4 2013-22.3%
Q3 2013+3.1%
Q2 2013-3.3%
Q1 2013+0.4%
Q4 2009-5.5%
Q3 2012-0.9%
Q2 2012-5.5%
Q1 2011-3.1%
Q1 2012+11.8%
Q4 2011+0.8%
Q3 2010+2.5%
Q3 2011+2.5%
Q2 2011-33.6%
Q4 2010-33.6%
Q2 2010-33.6%
Q1 2010-7.9%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro